Keyphrases
Receptor Antagonist
100%
Central Administration
100%
Melanocortin 4 Receptor (MC4R)
100%
Morphine
100%
Morphine Tolerance
100%
Hyperalgesia
100%
Morphine Withdrawal
100%
HS014
100%
MC4 Receptor
50%
Antinociceptive
37%
Chronic Morphine
25%
NDP-MSH
25%
Chronic Pain Treatment
25%
Chronic Effects
12%
Non-selective
12%
Receptor Modulation
12%
Tail-flick Test
12%
Antagonistic Interactions
12%
Melanocortin
12%
Supraspinal
12%
Osmotic Pump
12%
Isobolographic Analysis
12%
Intracerebroventricular Administration
12%
Chronic Intracerebroventricular Infusion
12%
Withdrawal Reaction
12%
Development Mechanism
12%
Acute Treatment
12%
Melanocortin System
12%
Additive Interaction
12%
Medicine and Dentistry
Hyperpathia
100%
Receptor Antagonist
100%
Morphine
100%
Morphine Tolerance
100%
Beta intermedin[11-22][11 (N Acetylcysteine) 14 [3 (2 Naphthyl) Dextro Alanine] 18 Cysteine 22 Aspartic Acid Amide] 11,18 Cyclic Disulfide
100%
Melanocortin 4 Receptor
100%
Chronic Pain
20%
Intermedin
20%
Intracerebroventricular Drug Administration
20%
Melanocortin
20%
Receptor
10%
Tail
10%
Morphine Withdrawal
10%
Withdrawal Reflex
10%
Receptor Modulation
10%
Antinociception
10%
Neuroscience
Receptor Antagonist
100%
Hyperalgesia
100%
Morphine
100%
Beta intermedin[11-22][11 (N Acetylcysteine) 14 [3 (2 Naphthyl) Dextro Alanine] 18 Cysteine 22 Aspartic Acid Amide] 11,18 Cyclic Disulfide
100%
Melanocortin 4 Receptor
100%
Melanocyte-Stimulating Hormone
18%
Melanocortin
18%
Receptor
9%
Agonist
9%
Receptor Modulation
9%
Withdrawal Reflex
9%
Morphine Withdrawal
9%
Pharmacology, Toxicology and Pharmaceutical Science
Receptor Antagonist
100%
Morphine
100%
Hyperalgesia
100%
Melanocortin 4 Receptor
100%
Beta intermedin[11-22][11 (N Acetylcysteine) 14 [3 (2 Naphthyl) Dextro Alanine] 18 Cysteine 22 Aspartic Acid Amide] 11,18 Cyclic Disulfide
100%
Intermedin
16%
Melanocortin
16%
Chronic Pain
16%
Receptor
8%
Additive Interaction
8%
Antinociception
8%